Richard Scolyer
#65,868
Most Influential Person Now
Pathologist and melanoma researcher
Richard Scolyer's AcademicInfluence.com Rankings
Richard Scolyerbiology Degrees
Biology
#3199
World Rank
#4927
Historical Rank
Pathology
#40
World Rank
#89
Historical Rank
Download Badge
Biology
Why Is Richard Scolyer Influential?
(Suggest an Edit or Addition)According to Wikipedia, Richard Anthony Scolyer is an Australian pathologist. He is a senior staff specialist in tissue pathology and diagnostic oncology at Royal Prince Alfred Hospital, co-medical director at the Melanoma Institute Australia, and Cojoint professor at the University of Sydney.
Richard Scolyer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Genomic Classification of Cutaneous Melanoma (2015) (2143)
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
- Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual (2017) (1458)
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
- Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. (2011) (957)
- Whole-genome landscapes of major melanoma subtypes (2017) (875)
- Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma (2012) (699)
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. (2018) (615)
- Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance (2012) (614)
- Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. (2012) (593)
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma (2011) (578)
- Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact (2014) (430)
- Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma (2003) (407)
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. (2019) (393)
- Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma (2012) (392)
- A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. (2015) (383)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Resistance to PD1/PDL1 checkpoint inhibition. (2017) (374)
- PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials (2015) (342)
- Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond (2018) (296)
- Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma (2013) (286)
- The significance of the Wnt pathway in the pathology of human cancers. (2004) (284)
- Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma (2014) (280)
- In vivo confocal microscopy for diagnosis of melanoma and basal cell carcinoma using a two-step method: analysis of 710 consecutive clinically equivocal cases. (2012) (278)
- Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma (2015) (270)
- The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of the face. (2010) (264)
- WHO classification of skin tumours (2018) (249)
- Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. (2012) (248)
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. (2019) (245)
- PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. (2015) (240)
- Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. (2015) (240)
- CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment (2018) (240)
- UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. (2015) (238)
- Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil (2003) (237)
- Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma (2017) (234)
- Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma (2017) (232)
- Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. (2014) (231)
- Tumours associated with BAP1 mutations (2013) (227)
- Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin (2018) (226)
- Overexpression of the Cell Adhesion Molecules DDR1, Claudin 3, and Ep-CAM in Metaplastic Ovarian Epithelium and Ovarian Cancer (2004) (219)
- High response rate to PD-1 blockade in desmoplastic melanomas (2017) (210)
- Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway (2015) (204)
- The Prognostic Importance of Tumor Mitotic Rate Confirmed in 1317 Patients With Primary Cutaneous Melanoma and Long Follow-Up (2004) (204)
- Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma (2007) (201)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site (2011) (194)
- Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade (2019) (193)
- Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies (2018) (192)
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
- EANM-EORTC general recommendations for sentinel node diagnostics in melanoma (2009) (187)
- Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c‐MET Limit Cancer Immunotherapy (2017) (185)
- Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy (2018) (184)
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) (2019) (183)
- BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. (2013) (181)
- MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma (2011) (176)
- Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? (2016) (174)
- Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome (2016) (173)
- Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma (2017) (171)
- The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. (2020) (166)
- Risk Assessment for Atypical Spitzoid Melanocytic Neoplasms Using FISH to Identify Chromosomal Copy Number Aberrations (2013) (163)
- Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma. (2011) (160)
- A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. (2014) (157)
- Interobserver Reproducibility of Histopathologic Prognostic Variables in Primary Cutaneous Melanomas (2003) (155)
- Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. (2015) (155)
- Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets (2019) (155)
- Myopericytoma: a unifying term for a spectrum of tumours that show overlapping features with myofibroma. A review of 14 cases (2006) (152)
- Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. (2014) (152)
- Genetic and morphologic features for melanoma classification (2010) (144)
- Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine (2008) (144)
- The role of cell cycle regulatory proteins in the pathogenesis of melanoma (2006) (138)
- Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care (2011) (138)
- Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients (2017) (136)
- Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination (2015) (133)
- Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. (2004) (129)
- Histomorphologic Assessment and Interobserver Diagnostic Reproducibility of Atypical Spitzoid Melanocytic Neoplasms With Long-term Follow-up (2014) (128)
- Outcome in 846 Cutaneous Melanoma Patients From a Single Center After a Negative Sentinel Node Biopsy (2004) (127)
- Cutaneous melanoma (2005) (127)
- Blue Nevi and Related Lesions: A Review Highlighting Atypical and Newly Described Variants, Distinguishing Features and Diagnostic Pitfalls (2009) (127)
- Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. (2019) (124)
- Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma (2021) (123)
- Cutaneous melanoma in the era of molecular profiling (2009) (123)
- Subungual Melanoma: A Study of 124 Cases Highlighting Features of Early Lesions, Potential Pitfalls in Diagnosis, and Guidelines for Histologic Reporting (2007) (123)
- The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. (2014) (122)
- Correlation Between Preoperative Lymphoscintigraphy and Metastatic Nodal Disease Sites in 362 Patients With Cutaneous Melanomas of the Head and Neck (2004) (122)
- PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients (2015) (121)
- Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition (2020) (119)
- Tumor Suppressor microRNAs Contribute to the Regulation of PD‐L1 Expression in Malignant Pleural Mesothelioma (2017) (119)
- Prognostic factors in cutaneous desmoplastic melanoma (2010) (118)
- Improving management and patient care in lentigo maligna by mapping with in vivo confocal microscopy. (2013) (118)
- Sentinel Lymph Node Biopsy in Histologically Ambiguous Melanocytic Tumors With Spitzoid Features (So-Called Atypical Spitzoid Tumors) (2008) (115)
- Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. (2010) (115)
- BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage (2013) (114)
- SPITZ NAEVUS VERSUS SPITZOID MELANOMA: WHEN AND HOW CAN THEY BE DISTINGUISHED? (2002) (113)
- Pathologic examination of sentinel lymph nodes from melanoma patients. (2008) (112)
- Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma (2018) (112)
- MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. (2017) (111)
- Sentinel Lymph Node Biopsy in Patients With Thin Primary Cutaneous Melanoma (2012) (111)
- Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma (2016) (110)
- A distinct molecular profile associated with mucinous epithelial ovarian cancer (2006) (108)
- Ultrasound Examination of Sentinel Nodes in the Initial Assessment of Patients With Primary Cutaneous Melanoma (2004) (107)
- Management of Merkel Cell Carcinoma: The Roles of Lymphoscintigraphy, Sentinel Lymph Node Biopsy and Adjuvant Radiotherapy (2008) (105)
- The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil (2004) (105)
- Tumor-associated B-cells induce tumor heterogeneity and therapy resistance (2017) (105)
- Pigmented Epithelioid Melanocytoma: Favorable Outcome After 5-year Follow-up (2009) (105)
- Pathologic Review of Negative Sentinel Lymph Nodes in Melanoma Patients With Regional Recurrence: A Clinicopathologic Study of 1152 Patients Undergoing Sentinel Lymph Node Biopsy (2003) (105)
- Diagnosis of cutaneous melanocytic tumours by four‐colour fluorescence in situ hybridisation (2009) (104)
- Phyllodes tumours of the breast: a clinicopathological analysis of 65 cases from a single institution. (2009) (103)
- Dermoscopic evaluation of nodular melanoma. (2013) (102)
- SOX2 contributes to melanoma cell invasion (2012) (102)
- Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. (2014) (102)
- Expression of glucose‐regulated stress protein GRP78 is related to progression of melanoma (2009) (101)
- Merkel Cell Carcinoma: Assessing the Effect of Wide Local Excision, Lymph Node Dissection, and Radiotherapy on Recurrence and Survival in Early-Stage Disease—Results From a Review of 82 Consecutive Cases Diagnosed Between 1992 and 2004 (2007) (101)
- Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma (2014) (95)
- Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. (2019) (94)
- Desmoplastic neurotropic melanoma (2008) (93)
- Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas (2009) (93)
- Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. (2003) (93)
- Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma (2005) (91)
- A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study). (2016) (88)
- The advantage of using a synoptic pathology report format for cutaneous melanoma (2007) (88)
- A Sentinel Node Biopsy Does Not Increase the Incidence of In-Transit Metastasis in Patients With Primary Cutaneous Melanoma (2005) (88)
- Desmoplastic melanoma: a diagnostic trap for the unwary. (2004) (88)
- Surgery for melanoma metastases of the gastrointestinal tract: indications and results. (2009) (87)
- Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility (2020) (87)
- Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. (2014) (86)
- Targeted high-resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primary cutaneous melanoma. (2009) (86)
- A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma (2015) (86)
- Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial (2022) (85)
- Data Set for Pathology Reporting of Cutaneous Invasive Melanoma (2013) (85)
- Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. (2006) (84)
- Recurrent inactivating RASA2 mutations in melanoma (2015) (83)
- A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients (2016) (81)
- Outcomes of Atypical Spitz Tumors With Chromosomal Copy Number Aberrations and Conventional Melanomas in Children (2013) (79)
- Radiotherapy for lentigo maligna: a literature review and recommendations for treatment (2014) (79)
- PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma (2016) (78)
- Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine (2012) (78)
- In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy (2015) (77)
- Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma (2007) (76)
- PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma (2013) (76)
- Epigenetic Changes of EGFR play an important role in BRAF inhibitor Resistant Cutaneous Melanomas (2014) (75)
- Genetic and clinico-pathologic analysis of metastatic uveal melanoma (2014) (75)
- Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER) (2013) (74)
- Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins (2010) (73)
- Epigenetic profiling for the molecular classification of metastatic brain tumors (2018) (73)
- Sentinel Node Biopsy Provides More Accurate Staging Than Elective Lymph Node Dissection in Patients With Cutaneous Melanoma (2004) (73)
- Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. (2002) (72)
- The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis☆ (2015) (72)
- Intrapatient Homogeneity of BRAFV600E Expression in Melanoma (2014) (72)
- State of the Art, Nomenclature, and Points of Consensus and Controversy Concerning Benign Melanocytic Lesions: Outcome of an International Workshop (2010) (72)
- Pathology of melanocytic lesions: New, controversial, and clinically important issues (2004) (71)
- IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence (2010) (71)
- Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. (2017) (70)
- Genetic alterations and personalized medicine in melanoma: progress and future prospects. (2014) (69)
- Proposed Quality Standards for Regional Lymph Node Dissections in Patients With Melanoma (2009) (69)
- LC/MS-Based Quantitative Proteomic Analysis of Paraffin-Embedded Archival Melanomas Reveals Potential Proteomic Biomarkers Associated with Metastasis (2009) (69)
- SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling (2018) (68)
- Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours (2005) (67)
- Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. (2020) (67)
- Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases (2015) (67)
- Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes (2009) (66)
- Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients (2007) (66)
- Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity (2020) (66)
- Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma. (2016) (66)
- Determination of prognosis in metastatic melanoma through integration of clinico‐pathologic, mutation, mRNA, microRNA, and protein information (2015) (66)
- Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours (2020) (65)
- Transforming growth factor-β1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system (2005) (65)
- SF3B1 and BAP1 mutations in blue nevus-like melanoma (2017) (65)
- Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8 mm Separates Higher-Risk and Lower-Risk Tumors (2018) (64)
- Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment (2014) (64)
- Diagnosis of metastatic melanoma by fine-needle biopsy: analysis of 2,204 cases. (2007) (64)
- PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors (2017) (64)
- Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion (2015) (64)
- Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. (2016) (63)
- Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. (2011) (63)
- Review and cross-validation of gene expression signatures and melanoma prognosis. (2012) (62)
- RIP1 Kinase Is an Oncogenic Driver in Melanoma. (2015) (62)
- The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a (2009) (62)
- Prognostic Importance of the Extent of Ulceration in Patients With Clinically Localized Cutaneous Melanoma (2012) (62)
- Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases. (2004) (62)
- Surgical biopsy with intra-operative frozen section. An accurate and cost-effective method for diagnosis of musculoskeletal sarcomas. (2006) (62)
- Increased p53 Protein Expression in Malignant Mammary Phyllodes Tumors (2002) (61)
- Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. (2019) (59)
- Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients (2009) (59)
- Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumour microenvironment and cross-resistance to immunotherapy in melanoma (2021) (59)
- The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro (2008) (59)
- Nevus/Melanocytoma/Melanoma: an emerging paradigm for classification of melanocytic neoplasms? (2011) (58)
- CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function (2019) (58)
- Histopathologic Excision Margin Affects Local Recurrence Rate: Analysis of 2681 Patients With Melanomas ≤2 mm Thick (2005) (58)
- Surveillance for treatment failure of lentigo maligna with dermoscopy and in vivo confocal microscopy: new descriptors (2014) (58)
- Histologically ambiguous ("borderline") primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy. (2010) (57)
- Increased c-kit (CD117) expression in malignant mammary phyllodes tumors (2004) (57)
- RAB27A promotes melanoma cell invasion and metastasis via regulation of pro‐invasive exosomes (2019) (57)
- Combined naevus: a benign lesion frequently misdiagnosed both clinically and pathologically as melanoma (2004) (57)
- False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy (2009) (56)
- Angiotropism is an Independent Predictor of Local Recurrence and In-transit Metastasis in Primary Cutaneous Melanoma (2008) (56)
- Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors (2009) (55)
- Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system (2016) (55)
- Spitz naevus: diagnostic problems and their management implications. (2004) (55)
- MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis (2015) (54)
- Dermoscopy and in vivo confocal microscopy are complementary techniques for diagnosis of difficult amelanotic and light‐coloured skin lesions (2016) (54)
- AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma (2013) (54)
- DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. (2014) (54)
- A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma (2012) (53)
- The Importance of Adequate Primary Tumor Excision Margins and Sentinel Node Biopsy in Achieving Optimal Locoregional Control for Patients With Thick Primary Melanomas (2013) (53)
- Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes. (2019) (52)
- Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma: a prospective, consecutive, cohort study of 168 cases (2016) (52)
- So‐called “malignant blue nevus” (2009) (52)
- Increased expression of apoptotic markers in melanoma (2003) (52)
- Absence of distinguishing senescence traits in human melanocytic nevi. (2012) (52)
- Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients (2018) (52)
- Isolated Limb Infusion for Advanced Soft Tissue Sarcoma of the Extremity (2008) (52)
- The detection and significance of melanoma micrometastases in sentinel nodes. (2008) (51)
- Melanoma pathology reporting and staging (2019) (51)
- Sentinel node biopsy for melanoma: Where have we been and where are we going? (2004) (50)
- Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. (2020) (50)
- Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients (2014) (50)
- The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers (2011) (49)
- Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma (2019) (49)
- INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas (2015) (49)
- Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma (2007) (49)
- Elemental bio-imaging of melanoma in lymph node biopsies. (2009) (48)
- Clinicopathologic Features of Incident and Subsequent Tumors in Patients with Multiple Primary Cutaneous Melanomas (2012) (48)
- Melanomas of unknown primary have a mutation profile consistent with cutaneous sun‐exposed melanoma (2013) (48)
- Pharmacologically antagonizing the CXCR4-CXCL12 chemokine pathway with AMD3100 inhibits sunlight-induced skin cancer. (2014) (48)
- Human Cancer Biology Distinguishing Clinicopathologic Features of Patients with V 600 E and V 600 K BRAF-Mutant Metastatic Melanoma (2012) (47)
- The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Case–Control Study (2016) (47)
- Interobserver Variation in the Histopathologic Reporting of Key Prognostic Parameters, Particularly Clark Level, Affects Pathologic Staging of Primary Cutaneous Melanoma (2009) (47)
- Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors (2013) (47)
- A highly recurrent RPS27 5'UTR mutation in melanoma (2014) (47)
- Absence of human papillomavirus in tonsillar squamous cell carcinomas from Chinese patients. (2003) (46)
- Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi (2017) (46)
- Reduced p16 and Increased Cyclin D1 and pRb Expression Are Correlated With Progression in Cutaneous Melanocytic Tumors (2009) (46)
- KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. (2019) (46)
- Molecular Genomic Profiling of Melanocytic Nevi. (2019) (45)
- Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial (2022) (45)
- Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. (2020) (45)
- Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling (2014) (45)
- Factors Predicting Recurrence and Survival in Sentinel Lymph Node-Positive Melanoma Patients (2011) (45)
- New evidence for geographic variation in the role of human papillomavirus in tonsillar carcinogenesis (2007) (44)
- Margins of excision and prognostic factors for cutaneous eyelid melanomas. (2013) (44)
- Oncogenic B-RAFV600E signaling induces the T-box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion (2012) (44)
- Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases (2012) (43)
- Desmoplastic Melanoma: A Heterogeneous Entity in Which Subclassification as “Pure” or “Mixed” May Have Important Prognostic Significance (2005) (43)
- Tumour Angiogenesis and p53 Protein Expression in Mammary Phyllodes Tumors (2003) (43)
- Outcome Following Sentinel Node Biopsy Plus Wide Local Excision Versus Wide Local Excision Only for Primary Cutaneous Melanoma: Analysis of 5840 Patients Treated at a Single Institution (2014) (43)
- Liver resection for metastatic melanoma: Equivalent survival for cutaneous and ocular primaries (2013) (43)
- Quality of histopathological reporting on melanoma and influence of use of a synoptic template (2010) (42)
- False Negative Sentinel Lymph Node Biopsies in Melanoma May Result From Deficiencies in Nuclear Medicine, Surgery, or Pathology (2008) (42)
- Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors (2015) (42)
- Sentinel lymph nodes in malignant melanoma: Extended histopathologic evaluation improves diagnostic precision (2004) (42)
- Plasma cells in primary melanoma. Prognostic significance and possible role of IgA (2016) (41)
- Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma (2020) (41)
- PDl1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. (2016) (41)
- Morphologic features of melanophages under in vivo reflectance confocal microscopy. (2010) (41)
- Primary cutaneous Ewing sarcoma/primitive neuroectodermal tumour: a clinicopathological analysis of seven cases highlighting diagnostic pitfalls and the role of FISH testing in diagnosis (2009) (41)
- Sex differences in oncogenic mutational processes (2019) (41)
- Intraoperative frozen-section evaluation can reduce accuracy of pathologic assessment of sentinel nodes in melanoma patients. (2005) (41)
- Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). (2009) (41)
- Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. (2021) (40)
- Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression (2013) (40)
- Reflectance confocal microscopy for diagnosis of mammary and extramammary Paget’s disease (2013) (39)
- Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. (2015) (39)
- Melanocytic lesions of the face: diagnostic pitfalls. (2004) (39)
- Pathogenic mechanisms in the initiation and progression of mammary phyllodes tumours (2009) (39)
- Sentinel Node Positive Melanoma Patients: Prediction and Prognostic Significance of Nonsentinel Node Metastases and Development of a Survival Tree Model (2010) (39)
- Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms. (2016) (38)
- Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation (2016) (38)
- Critical Assessment of Clinical Prognostic Tools in Melanoma (2016) (38)
- Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis (2012) (38)
- Surgical Management of Melanoma Lung Metastasis: An Analysis of Survival Outcomes in 292 Consecutive Patients (2012) (38)
- CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells. (2020) (37)
- PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials (2016) (37)
- Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma (2012) (37)
- Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. (2017) (37)
- Cooperation between surgical oncologists and pathologists: a key element of multidisciplinary care for patients with cancer. (2004) (37)
- BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma (2013) (37)
- Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients (2019) (37)
- Skp2-Mediated Stabilization of MTH1 Promotes Survival of Melanoma Cells upon Oxidative Stress. (2017) (37)
- The Complex Relationships Between Sentinel Node Positivity, Patient Age, and Primary Tumor Desmoplasia: Analysis of 2303 Melanoma Patients Treated at a Single Center (2008) (36)
- The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro (2011) (36)
- 1220PDPhase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma (2017) (36)
- Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). (2009) (36)
- Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1–2 mm in Thickness): Analysis of 2131 Patients Treated at a Single Center (2016) (36)
- Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells (2014) (35)
- Counting mitoses: SI(ze) matters! (2021) (35)
- Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors (2020) (35)
- Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. (2019) (35)
- Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours (2009) (35)
- CAN PHYLLODES TUMOURS OF THE BREAST BE DISTINGUISHED FROM FIBROADENOMAS USING FINE NEEDLE ASPIRATION CYTOLOGY? (2001) (34)
- Melanoma Patients with an Unknown Primary Tumor Site Have a Better Outcome than Those with a Known Primary Following Therapeutic Lymph Node Dissection for Macroscopic (Clinically Palpable) Nodal Disease (2014) (34)
- Pravastatin‐induced lichenoid drug eruption (2006) (34)
- Combined targeted therapy and immunotherapy in the treatment of advanced melanoma (2012) (34)
- Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC) (2019) (33)
- Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma (2012) (33)
- Telomere sequence content can be used to determine ALT activity in tumours (2018) (33)
- TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells (2014) (33)
- BAP1 expression in cutaneous melanoma: a pilot study. (2013) (33)
- Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas (2017) (33)
- Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. (2021) (33)
- Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer. (2019) (33)
- Primary Melanoma of the Lung (2007) (32)
- Pathology Review Significantly Affects Diagnosis and Treatment of Melanoma Patients: An Analysis of 5011 Patients Treated at a Melanoma Treatment Center (2014) (32)
- Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. (2016) (32)
- Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes (2013) (32)
- Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility (2018) (32)
- Sentinel Node Status Prediction by Four Statistical Models: Results From a Large Bi-Institutional Series (n = 1132) (2009) (32)
- Subungual Melanoma of the Hand (2018) (31)
- Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma (2015) (31)
- Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. (2009) (30)
- Melanoma of the Vulva and Vagina: Principles of Staging and Their Relevance to Management Based on a Clinicopathologic Analysis of 85 Cases (2015) (30)
- Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas (2019) (30)
- Oncogenic suppression of PHLPP1 in human melanoma (2014) (30)
- Sentinel Lymph Nodes Containing Very Small (<0.1 mm) Deposits of Metastatic Melanoma Cannot Be Safely Regarded as Tumor-Negative (2012) (30)
- BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume (2015) (30)
- p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours (2010) (30)
- Isolated melanoma in the lung where there is no known primary site: metastatic disease or primary lung tumour? (2005) (30)
- New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. (2015) (29)
- An extended antibody microarray for surface profiling metastatic melanoma. (2010) (29)
- Enzinger and Weiss's Soft Tissue Tumors: Fourth Edition (2002) (29)
- BRM and BRG1 subunits of the SWI/SNF chromatin remodelling complex are downregulated upon progression of benign skin lesions into invasive tumours (2011) (29)
- Identification of TFG (TRK‐fused gene) as a putative metastatic melanoma tumor suppressor gene (2012) (29)
- Increasing Tumor Thickness is Associated with Recurrence and Poorer Survival in Patients with Merkel Cell Carcinoma (2012) (29)
- Eccrine porocarcinoma of the upper eyelid (2005) (29)
- The important role of radiation treatment in the management of Merkel cell carcinoma (2013) (28)
- Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy (2020) (28)
- Poor Adherence to National Clinical Management Guidelines: A Population-Based, Cross-Sectional Study of the Surgical Management of Melanoma in New South Wales, Australia (2017) (28)
- Intramuscular dendritic fibromyxolipoma: Myxoid variant of spindle cell lipoma? (2003) (28)
- Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center (2017) (27)
- Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling (2021) (27)
- In vivo and ex vivo proton MR spectroscopy of primary and secondary melanoma. (2005) (27)
- Total Sentinel Lymph Node Tumor Size Predicts Nonsentinel Node Metastasis and Survival in Patients with Melanoma (2010) (27)
- The molecular profile of metastatic melanoma in Australia. (2016) (27)
- Surgical management of primary cutaneous melanoma: excision margins and the role of sentinel lymph node examination. (2006) (27)
- Atypical Spitzoid neoplasms: a review of potential markers of biological behavior including sentinel node biopsy (2014) (27)
- Recent insights into the molecular pathogenesis of mammary phyllodes tumours (2013) (27)
- Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets). (2021) (27)
- BRAFV600E and NRASQ61L/Q61R mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting (2016) (27)
- Failure to remove true sentinel nodes can cause failure of the sentinel node biopsy technique: Evidence from antimony concentrations in false-negative sentinel nodes from melanoma patients (2004) (27)
- Pitfalls and important issues in the pathologic diagnosis of melanocytic tumors. (2010) (27)
- Tumour gene expression signature in primary melanoma predicts long-term outcomes (2020) (26)
- Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients (2017) (26)
- Trajectories of premalignancy during the journey from melanocyte to melanoma. (2018) (26)
- Treatment and Prognostic Significance of Positive Interval Sentinel Nodes in Patients with Primary Cutaneous Melanoma (2011) (26)
- Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of Stage III patients (2016) (26)
- Diagnostic Accuracy of Fine Needle Biopsy for Metastatic Melanoma and Its Implications for Patient Management (2007) (26)
- Incomplete biopsy of melanocytic lesions can impair the accuracy of pathological diagnosis. (2006) (26)
- Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour (2005) (26)
- Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value (2020) (26)
- Comprehensive analysis of cutaneous and uveal melanoma liver metastases (2020) (25)
- Cytoplasmic expression of nm23 predicts the potential for cerebral metastasis in patients with primary cutaneous melanoma (2004) (25)
- Anatomic position determines oncogenic specificity in melanoma (2020) (25)
- SPINAL CHLOROMA PRESENTING WITH TRIPLEGIA IN AN ALEUKAEMIC PATIENT (2001) (25)
- Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers. (2019) (24)
- Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. (2014) (24)
- Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. (2018) (24)
- Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors. (2017) (23)
- Melanoma pathology: important issues for clinicians involved in the multidisciplinary care of melanoma patients. (2011) (23)
- TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone. (2010) (23)
- Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials (2019) (23)
- Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling (2018) (23)
- Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma. (2015) (23)
- Immunohistochemical stains fail to increase the detection rate of micrometastatic melanoma in completion regional lymph node dissection specimens (2004) (23)
- Pigmented epithelioid melanocytoma. (2004) (23)
- Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients. (2013) (23)
- p16INK4a deficiency promotes DNA hyper‐replication and genetic instability in melanocytes (2013) (23)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Targeting Nodal in Conjunction with Dacarbazine Induces Synergistic Anticancer Effects in Metastatic Melanoma (2015) (22)
- In Vivo Reflectance Confocal Microscopy for the Diagnosis of Melanoma and Melanotic Macules of the Lip (2017) (22)
- Fine-needle biopsy of metastatic melanoma: clinical use and new applications. (2010) (22)
- BRAF mutation by age-decade and body mass index in metastatic melanoma. (2011) (22)
- Resistance to PD 1 / PDL 1 checkpoint inhibition (2016) (22)
- An unusual variant of intraneural ganglion of the common peroneal nerve (2006) (22)
- Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. (2019) (22)
- High molecular weight–melanoma‐associated antigen as a biomarker of desmoplastic melanoma (2010) (22)
- Rapid detection of metastatic melanoma in lymph nodes using proton magnetic resonance spectroscopy of fine needle aspiration biopsy specimens (2003) (22)
- Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features (2018) (21)
- The importance of mitotic rate as a prognostic factor for localized primary cutaneous melanoma (2006) (21)
- Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence (2020) (21)
- The importance of mitotic rate as a prognostic factor for localized primary cutaneous melanoma (2006) (21)
- Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma (2012) (21)
- Reproducibility of AJCC Staging Parameters in Primary Cutaneous Melanoma: An Analysis of 4,924 Cases (2013) (21)
- The importance of mitotic rate as a prognostic factor for localized primary cutaneous melanoma (2006) (21)
- The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene (2016) (21)
- Nicotinamide for skin cancer chemoprevention: effects of nicotinamide on melanoma in vitro and in vivo. (2020) (21)
- Myxoid variant of adrenocortical carcinoma: Report of a unique case (2006) (21)
- Human 8-oxoguanine-DNA glycosylase-1 is downregulated in human basal cell carcinoma. (2012) (21)
- The absence of Brm exacerbates photocarcinogenesis (2012) (20)
- Survival in patients with desmoplastic melanoma. (2006) (20)
- Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas (2014) (20)
- Evidence-Based Clinical Practice Guidelines for the Management of Patients with Lentigo Maligna (2019) (20)
- Histological expression of tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL) in human primary melanoma (2004) (20)
- Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma (2020) (20)
- Use of multiple cytometric markers improves discrimination between benign and malignant melanocytic lesions: a study of DNA microdensitometry, karyometry, argyrophilic staining of nucleolar organizer regions and MIB1-Ki67 immunoreactivity (2003) (19)
- Cytologic features of metastatic and recurrent melanoma in patients with primary cutaneous desmoplastic melanoma. (2008) (19)
- Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. (2020) (19)
- Melanoma Metastases in Regional Lymph Nodes Are Accurately Detected by Proton Magnetic Resonance Spectroscopy of Fine-Needle Aspirate Biopsy Samples (2005) (19)
- Polymorphous Low-Grade Adenocarcinoma in the Lung: A Case Report (2004) (19)
- Sex Differences in Melanoma Survival are Not Related to Mitotic Rate of the Primary Tumor (2015) (19)
- whole-exome sequencing identifies (2016) (19)
- Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. (2006) (19)
- Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications (2015) (19)
- Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors (2013) (18)
- Targeted Therapy Database (TTD): A Model to Match Patient's Molecular Profile with Current Knowledge on Cancer Biology (2010) (18)
- The history and future of melanoma staging (2004) (18)
- Parachordoma is not distinguishable from axial chordoma using immunohistochemistry (2004) (18)
- Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens (2018) (18)
- Low meprin α expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries (2006) (18)
- Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis (2020) (18)
- Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma (2022) (18)
- Merkel cell carcinoma with fibrosarcomatous differentiation. (2008) (18)
- OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO). (2018) (18)
- Sentinel lymph node biopsy for melanoma: aspects of pathologic assessment. (2008) (18)
- Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. (2016) (18)
- Selective sentinel lymphadenectomy: progress to date and prospects for the future. (2005) (18)
- Estimated risk of progression of lentigo maligna to lentigo maligna melanoma (2020) (18)
- The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics. (2021) (17)
- Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. (2020) (17)
- Classification of high risk basal cell carcinoma subtypes: experience of the ONTRAC study with proposed definitions and guidelines for pathological reporting. (2016) (17)
- Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma. (2020) (17)
- Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients (2014) (17)
- Hepatocellular carcinoma metastasizing to the orbit diagnosed by fine needle aspiration cytology. (1999) (17)
- Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients (2017) (17)
- Lymphoma occurring in patients with cutaneous melanoma (2010) (17)
- E-cadherin expression in the epithelial components of mammary phyllodes tumors. (2012) (17)
- Clinical and pathological features of metastases of primary cutaneous desmoplastic melanoma (2011) (17)
- The diagnostic value of adding dynamic scintigraphy to standard delayed planar imaging for sentinel node identification in melanoma patients (2011) (16)
- A novel hypoxia-associated subset of FN1highMITFlow melanoma cells: identification, characterization, and prognostic value (2014) (16)
- Epithelioid and spindle cell haemangioma of bone (2007) (16)
- Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome (2022) (16)
- The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence (2020) (16)
- Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial. (2019) (16)
- Antimony by ICP-MS as a marker for sentinel lymph nodes in melanoma patients. (2003) (16)
- Myoid Angioendothelioma of the Spleen (2004) (16)
- Subungual Melanoma of the Hand. (1996) (16)
- RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells (2018) (16)
- Pigmented epithelioid melanocytoma: a recently described melanocytic tumour of low malignant potential. (2010) (15)
- First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality (2015) (15)
- Programmed Death-Ligand 1 Expression in a Large Cohort of Pediatric Patients With Solid Tumor and Association With Clinicopathologic Features in Neuroblastoma. (2017) (15)
- The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Population‐based data on diagnosis and management (2018) (15)
- Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo). (2017) (15)
- Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA (2020) (15)
- Antimony concentrations in nodal tissue can confirm sentinel node identity (2004) (15)
- Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<0.1 mm) Sentinel Lymph Node Metastases (2015) (15)
- Mutation load in melanoma is affected by MC1R genotype (2017) (15)
- Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. (2021) (15)
- Adjuvant radiotherapy after lymphadenectomy in melanoma patients: Final results of an intergroup randomized trial (ANZMTG 0.1.02/TROG 02.01). (2013) (15)
- Involvement of α‐ and β‐catenins and E‐cadherin in the development of mammary phyllodes tumours (2012) (15)
- Computer-assisted diagnosis for skin cancer: have we been outsmarted? (2017) (15)
- Inter‐ and intrapatient heterogeneity of indoleamine 2,3‐dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment (2019) (15)
- Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells (2017) (15)
- Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010 (2011) (14)
- SOX10 expression in cutaneous scars: a potential diagnostic pitfall in the evaluation of melanoma re-excision specimens. (2016) (14)
- Argyrophilic Staining of Nucleolar Organizer Region Count and Morphometry in Benign and Malignant Melanocytic Lesions (2003) (14)
- Targeting NK Cells to Enhance Melanoma Response to Immunotherapies (2021) (14)
- γδ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival (2021) (14)
- The tumour immune landscape and its implications in cutaneous melanoma (2020) (14)
- Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. (2020) (14)
- Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. (2021) (14)
- Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab (2020) (14)
- 18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma (2019) (14)
- A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma (2019) (14)
- Epidermolysis bullosa acquisita requiring multiple oesophageal dilatations (2008) (14)
- Digital papillary adenocarcinoma: a tumour that should be considered in the differential diagnosis of neoplasms involving the digits (2013) (14)
- 5‐Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms (2017) (14)
- Fine-needle biopsy as a diagnostic technique for metastatic melanoma. (2008) (14)
- LNK suppresses interferon signaling in melanoma (2019) (14)
- Epiphyseal osteoblastoma-like osteosarcoma (2003) (14)
- Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients (2020) (14)
- Differentiating benign nevi from malignant melanoma using DNA microdensitometry and karyometry and maturation: a zonal comparison, correlation and multivariate analysis. (2002) (14)
- Frontiers in melanocytic pathology. (2004) (14)
- Disturbed protein–protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden (2013) (14)
- The prognostic significance of isolated immunohistochemically positive cells in sentinel lymph nodes of melanoma patients. (2008) (14)
- Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC) (2022) (13)
- Aggressive endometriosis: report of a case. (2000) (13)
- Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma (2019) (13)
- Association Between Melanoma Detected During Routine Skin Checks and Mortality. (2021) (13)
- Safety and tolerability of an intratumorally injected DNAzyme , Dz 13 , in patients with nodular basal-cell carcinoma : a phase 1 first-inhuman trial ( DISCOVER ) (2014) (13)
- Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. (2022) (13)
- Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial. (2021) (13)
- Breslow Thickness Measurements of Melanomas Around American Joint Committee on Cancer Staging Cut-Off Points: Imprecision and Terminal Digit Bias Have Important Implications for Staging and Patient Management (2016) (13)
- Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model (2020) (13)
- Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing (2017) (13)
- Endocrine mucin producing sweat gland carcinoma: a clinicopathological analysis of three cases. (2012) (13)
- Lentiginous melanoma (lentigo maligna and lentigo maligna melanoma) in Australia: clinicopathological characteristics, management and recurrence rates after 10‐year follow‐up at a tertiary centre (2021) (12)
- The Optimum Excision Margin and Regional Node Management for Primary Cutaneous T3 Melanomas (2–4 mm in Thickness): A Retrospective Study of 1587 Patients Treated at a Single Center (2014) (12)
- Preliminary results from the international neoadjuvant melanoma consortium (INMC). (2017) (12)
- Atypical Ewing sarcoma breakpoint region 1 fluorescence in‐situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases (2016) (12)
- A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide. (2019) (12)
- Condylomata acuminata of the urinary bladder with HPV 11. (2005) (12)
- Correction to: Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond (2018) (12)
- BAP1-inactivated spitzoid naevi. (2015) (12)
- Melanotic schwannoma mimicking metastatic pigmented melanoma: a pitfall in cytological diagnosis. (2010) (12)
- Melanocytic nevus with focal atypical epithelioid components (clonal nevus) is a combined nevus. (2007) (12)
- G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma (2021) (12)
- Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma. (2016) (12)
- The Prognostic Value of Tumor Mitotic Rate and Other Clinicopathologic Factors in Patients with Locoregional Recurrences of Melanoma (2010) (12)
- Biospecimen banking: The pathway to personalized medicine for patients with cancer (2013) (12)
- Mucosal‐associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy‐related colitis in a pathology distinct from ulcerative colitis (2020) (11)
- Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma. (2015) (11)
- Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours (2006) (11)
- Germline BAP1 mutations also predispose to cutaneous squamous cell carcinoma. (2017) (11)
- Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts (2018) (11)
- Melanoma protective antitumor immunity activated by catalytic DNA (2018) (11)
- Multiple checkpoints on the long road towards cancer immunotherapy (2015) (11)
- Can We Better Identify Thin Cutaneous Melanomas That are Likely to Metastasize and Cause Death? (2012) (11)
- Intra-patient heterogeneity of BRAF mutation status: fact or fiction? (2013) (11)
- Melanoma exhibiting cartilaginous differentiation (2010) (11)
- LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial (2021) (11)
- Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas. (2017) (11)
- FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center (2018) (11)
- The site of infection and ethnicity of the patient influence the biological pathways to HPV-induced mucosal cancer (2004) (11)
- Collaboration between clinicians and pathologists: a necessity for the optimal management of melanoma patients (2005) (11)
- Peritoneal melanosis associated with metastatic melanoma involving the omentum. (2012) (11)
- The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma (2019) (11)
- Selective loss of wild-type p16(INK4a) expression in human nevi. (2011) (11)
- In vivo reflectance confocal microscopy for evaluating melanoma of the lip and its differential diagnoses. (2017) (11)
- Association of anti-thyroid antibodies in checkpoint inhibitor associated thyroid immune related adverse events. (2022) (10)
- Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes (2015) (10)
- Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas (2020) (10)
- Cytological features of melanoma in exfoliative fluid specimens (2009) (10)
- 3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate (2015) (10)
- The regenerating naevus. (2016) (10)
- Genetic drivers of non‐cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape (2021) (9)
- Re-evaluation of a scoring system to predict nonsentinel-node metastasis and prognosis in melanoma patients. (2010) (9)
- Pagetoid spread of melanocytes in Spitz naevi: authors' reply (2002) (9)
- A multicentre study of naevus‐associated melanoma vs. de novo melanoma, tumour thickness and body site differences * (2021) (9)
- Mitotic rate in melanoma should be recorded as the number of mitoses per mm² (not per high power field): surgeons tell your pathologists! (2013) (9)
- Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. (2021) (9)
- Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system (2020) (9)
- Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition (2021) (9)
- Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. (2020) (9)
- Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma. (2018) (9)
- Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets (2021) (8)
- Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study. (2020) (8)
- Author Correction: Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin (2019) (8)
- Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. (2021) (8)
- Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines (2021) (8)
- The role of intra-operative pathological evaluation in the management of musculoskeletal tumours. (2009) (8)
- Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging (2017) (8)
- LBA39 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study (2021) (8)
- Melanoma - a management guide for GPs. (2012) (8)
- Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial. (2022) (8)
- Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma (2012) (8)
- Radiation Recall Dermatitis After Pre-Sensitization With Pegylated Liposomal Doxorubicin (2009) (8)
- Histological regression in melanoma: impact on sentinel lymph node status and survival (2021) (8)
- Erratum: Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas (ann surg oncol (2012) 19 (1024-1033) DOI: 10.1245/S10434-011-2058-8) (2013) (8)
- Unusual case of subcutaneous panniculitis‐like T‐cell lymphoma (2004) (8)
- Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions (2017) (7)
- Tumors and tumor-like lesions of the lung (1999) (7)
- Location of melanoma metastases in sentinel lymph nodes: what are the implications for histologic processing of sentinel lymph nodes in routine practice? (2010) (7)
- Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial (2021) (7)
- Progressive visual loss in a patient with presumed temporal arteritis despite treatment: how to make the diagnosis (2004) (7)
- Diagnostic value of 8.5 T magnetic resonance spectroscopy of benign and malignant skin lesion biopsies (2010) (7)
- PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma (2021) (7)
- Controversies and evolving concepts in the diagnosis, classification and management of lentigo maligna (2013) (7)
- Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus? (2022) (7)
- HYALINISING SPINDLE CELL TUMOUR WITH GIANT ROSETTES: REPORT OF A CASE WITH UNUSUAL FEATURES INCLUDING ORIGINAL HISTOLOGICAL AND ULTRASTRUCTURAL OBSERVATIONS (2001) (7)
- Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma. (2010) (7)
- 1256TiPA Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D+T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial) (2017) (7)
- Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi). (2011) (6)
- Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis (2018) (6)
- An unusual pleural spindle cell tumour: Parts 1 and 2 (2002) (6)
- Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system. (2019) (6)
- Abstract 5734: Gut microbiota predicts response and toxicity with neoadjuvant immunotherapy (2020) (6)
- Diffuse melanosis cutis in the setting of BRAFV600E metastatic melanoma (2014) (6)
- Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease (2022) (6)
- Tumor-infiltrating lymphocytes and mitotic index in metastatic melanoma as predictors of patient survival (2010) (6)
- Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma (2021) (6)
- Eruptive disseminated Spitz naevus (EDSN) in a young girl of Indian origin (2015) (6)
- BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. (2015) (6)
- Molecular Profiling of Noncoding Mutations Distinguishes Nevoid Melanomas From Mitotically Active Nevi in Pregnancy (2019) (6)
- Hypermethylation of Circulating Free DNA in Cutaneous Melanoma (2019) (6)
- Melanoma management in 2007. (2007) (6)
- Follicular dendritic cell sarcoma of the lung: a report of two cases highlighting its pathological features and diagnostic pitfalls. (2011) (6)
- Surgical management of the neck in patients with metastatic melanoma in parotid lymph nodes (2019) (6)
- A multi-step classifier addressing cohort heterogeneity improves performance of prognostic biomarkers in three cancer types (2016) (6)
- Conditional survival estimates for cancer patients (2017) (6)
- Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma (2015) (6)
- Synchronous and metachronous malignancies in patients with melanoma: a clinicopathologic study highlighting the role of fine-needle biopsy cytology and potential diagnostic pitfalls (2010) (6)
- Multiplex melanoma families are enriched for polygenic risk (2020) (6)
- Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials (2020) (6)
- Improving diagnostic accuracy for suspicious melanocytic skin lesions: New Australian melanoma clinical practice guidelines stress the importance of clinician/pathologist communication. (2019) (6)
- Tumoural calcium pyrophosphate dihydrate crystal deposition disease (tophaceous pseudogout) of the hand: a report of two cases including one with a previously unreported associated florid reactive myofibroblastic proliferation. (2008) (6)
- Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis (2021) (6)
- Identification of new prognostic biomarkers for Stage III metastatic melanoma patients (2013) (6)
- Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients (2014) (6)
- Recurrent inactivating RASA 2 mutations in melanoma (6)
- Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis. (2021) (6)
- Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors (2020) (6)
- Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker (2020) (6)
- Abstract 2822: Low intestinal microbial diversity is associated with severe immune-related adverse events and lack of response to neoadjuvant combination antiPD1, anti-CTLA4 immunotherapy (2019) (6)
- Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms (2021) (6)
- The “Tricky Business” of Identifying Mechanisms of Resistance to Anti–PD-1 (2017) (6)
- Test and Teach Number Ninety-Six: Part 2 (1999) (5)
- External validation of a prognostic model to predict survival of patients with sentinel node‐negative melanoma (2019) (5)
- Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients (2007) (5)
- Staging of Cutaneous Melanoma: Is There Room for Further Improvement? (2018) (5)
- Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin (2018) (5)
- Punch ‘scoring’: a technique that facilitates melanoma diagnosis of clinically suspicious pigmented lesions (2018) (5)
- Predicting sentinel node positivity in patients with melanoma: external validation of a risk‐prediction calculator (the Melanoma Institute Australia nomogram) using a large European population‐based patient cohort * (2021) (5)
- Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D+T) in BRAF V600 mutant resectable stage IIIb/c/d melanoma (NeoTrio trial). (2018) (5)
- Phase 3 International Trial of Adjuvant Whole Brain Radiotherapy (WBRT) or Observation (OBS) Following Local Treatment of 1-3 Melanoma Brain Metastases (MBMs) (2019) (5)
- Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi. (2021) (5)
- Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study (2020) (5)
- The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment. (2022) (5)
- Retroperitoneal Inflammatory Liposarcoma in a Patient with Non-Hodgkin Lymphoma: A Report Highlighting Diagnostic Pitfalls (2010) (5)
- Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy (2022) (5)
- Lethal melanoma in children: a clinicopathological study of 12 cases. (2016) (5)
- Human Melanoma Cell Need SIRT5 to Survive (2016) (5)
- The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: a retrospective cohort study. (2020) (5)
- Dermoscopic features and screening strategies for the detection of small‐diameter melanomas (2022) (5)
- Atypical fibroxanthoma: differential diagnosis from other sarcomatoid skin lesions (2010) (5)
- Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials. (2022) (5)
- Angiomatoid Spitz naevus: novel observations and clues to diagnosis of a rare variant. (2016) (5)
- Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study (2022) (4)
- GLI activated epithelioid cell tumour: report of a case and proposed new terminology. (2020) (4)
- Test and teach. Number ninety six: Part 1. Inverted duct papilloma of minor salivary gland origin. (1999) (4)
- ACUTE BASOPHILIC LEUKEMIA PRESENTING WITH ABNORMAL LIVER FUNCTION TESTS AND THE ABSENCE OF BLAST CELLS IN THE PERIPHERAL BLOOD (2000) (4)
- Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics. (2022) (4)
- L3 Update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients (2020) (4)
- From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50years. (2019) (4)
- Middle lobe syndrome due to obstructing solitary bronchial papilloma. (1999) (4)
- Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition (2020) (4)
- Expression of NGF/proNGF and Their Receptors TrkA, p75NTR and Sortilin in Melanoma (2022) (4)
- Prognosis, Staging, and Reporting of Melanomas (2019) (4)
- L1CAM and laminin vascular network: Association with the high-risk replacement histopathologic growth pattern in uveal melanoma liver metastases (2022) (4)
- Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. (2020) (4)
- Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study (2022) (4)
- Confocal microscopy, dermoscopy, and histopathology features of atypical intraepidermal melanocytic proliferations associated with evolution to melanoma in situ (2021) (4)
- Advances in melanoma: revolutionary progress delivering improved patient management and outcomes. (2016) (4)
- High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy (2021) (4)
- Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis (2022) (4)
- The prognostic significance of microsatellites in cutaneous melanoma (2020) (4)
- Surgical Strategies and Histopathologic Issues in the Management of Lentigo Maligna (2009) (4)
- Borderline lepromatous leprosy presenting as a single cutaneous plaque (2005) (4)
- Publication metrics: what do they mean? (2020) (4)
- Protocol for the Examination of Biopsy Specimens From Patients With Melanoma of the Skin (2019) (4)
- Prognostic impact of cancer-testis antigen expression in primary cutaneous melanoma. (2009) (4)
- Confirmation of Sentinel Lymph Node Identity by Analysis of Fine-Needle Biopsy Samples Using Inductively Coupled Plasma–Mass Spectrometry (2008) (4)
- Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan (2019) (4)
- Primary oesophageal melanoma - a case report (2014) (4)
- Not all melanomas are created equal: a review and call for more research into nodular melanoma (2021) (4)
- Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites (2022) (4)
- Targeting the Microbiome to Overcome Resistance. (2021) (4)
- Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. (2020) (4)
- Management of pigmented skin lesions during pregnancy. (2019) (4)
- Melanin bleaching in argyrophilic staining of AgNORs in pigmented lesions: a morphometric evaluation. (2002) (3)
- Multi-trait genetic analysis identifies auto-immune loci associated with cutaneous melanoma. (2021) (3)
- Cellular blue naevus involving the urinary bladder. (2012) (3)
- The Neuropathology of Dementia: Alcoholism and dementia (2004) (3)
- Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility (2020) (3)
- Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM). (2017) (3)
- Paratesticular rhabdomyoma. (2007) (3)
- Predicting Sentinel Node Status in Patients With Melanoma: Does Gene Expression Profiling Improve Accuracy? (2020) (3)
- Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations (2021) (3)
- Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study. (2019) (3)
- Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy? (2015) (3)
- Sentinel node biopsy is more accurate than elective lymph node dissection in determining the regional node status of patients with cutaneous melanoma (2004) (3)
- Oral nicotinamide to reduce actinic cancer: A phase 3 double-blind randomized controlled trial. (2015) (3)
- Intestinal microbiota predict response and toxicities during anti-PD-1/anti-CTLA-4 immunotherapy (2020) (3)
- Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life (2019) (3)
- IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma (2023) (3)
- Pigmented Paget's disease of the nipple mistaken for melanoma in situ: a diagnostic pitfall for the unwary. (2018) (3)
- Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms (2022) (3)
- Reply to M. Perier-Muzet et al. (2014) (3)
- How anti-PD1 treatments are changing the management of melanoma. (2014) (3)
- Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome (2022) (3)
- Multiple primary cutaneous melanomas: recent studies highlight features associated with more indolent behaviour. (2013) (3)
- Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy. (2019) (3)
- Test and teach Number Ninety-Four: Part 1 (1999) (3)
- Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma (2022) (3)
- Primary dermal melanoma: clinical behaviour, prognosis and treatment. (2020) (3)
- Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells (2019) (3)
- Abstract 975: Liver metastases (mets) induce systemic immunosuppression and immunotherapy resistance in metastatic melanoma (2019) (3)
- A practical guide on the use of imiquimod cream to treat lentigo maligna (2021) (3)
- Management of pigmented skin lesions in childhood and adolescence. (2019) (2)
- Premalignancy: the lull before the storm. (2013) (2)
- Germline variants are associated with increased primary melanoma tumor thickness at diagnosis (2020) (2)
- A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study. (2020) (2)
- Prominent angiotropism in a small atypical spitzoid dysplastic melanocytic naevus: what is its significance? (2013) (2)
- Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement. (2023) (2)
- The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultra-thick melanomas (≥15mm in thickness). (2022) (2)
- Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA (2022) (2)
- Asymptomatic linear pigmentation of the skin (2013) (2)
- Pigmented epithelioid melanocytoma. Authors' reply (2004) (2)
- bcGST—an interactive bias‐correction method to identify over‐represented gene‐sets in boutique arrays (2018) (2)
- Completion lymph node dissection in melanoma patients with positive sentinel lymph nodes. (2013) (2)
- Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting (2022) (2)
- Biology and genetics of acquired and congenital melanocytic naevi. (2022) (2)
- Isolated Imunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System. (2019) (2)
- BRAF (v600e) and NRAS (q61r/q61l) mutation analysis using immunohistochemistry: Implications for routine mutation testing of melanoma samples. (2016) (2)
- Atypical naevus spilus: detection by in vivo confocal microscopy (2014) (2)
- Challenging and unusual cases: Case 4. Malignant mesothelioma presenting as an anterior mediastinal mass. (2003) (2)
- Cutaneous metastasis of epithelioid haemangioendothelioma. (2009) (2)
- Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy (2022) (2)
- Repeated Suberythemal UVB Preexposure Protects against High-Dose UVB-Induced Expression of Vitamin D Receptor Protein in Human Skin (2011) (2)
- Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation (2016) (2)
- BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting (2021) (2)
- Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study (2022) (2)
- Clinical management of melanocytic tumours of uncertain malignant potential (MelTUMPs), including melanocytomas: A systematic review and meta‐analysis (2022) (2)
- Punch biopsy of melanoma causing tumour cell implantation: Another peril of utilising partial biopsies for melanocytic tumours (2015) (2)
- Neoadjuvant Immunotherapy in Melanoma – The New Frontier (2021) (2)
- LETTERS TO THE EDITOR (2006) (2)
- Estimating the potential impact of interventions to reduce over‐calling and under‐calling of melanoma (2021) (2)
- Epigenetic pro fi ling for the molecular classi fi cation of metastatic brain tumors (2019) (2)
- Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets). (2019) (2)
- Test and Teach Number Ninety Six: Part 1 (1999) (2)
- Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management. (2020) (2)
- Interobserver agreement in the histopathological classification of desmoplastic melanomas. (2023) (1)
- Comment on "Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma". (2019) (1)
- Authors' response to a reply to ‘A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients’ (2017) (1)
- Classification and Histopathology of Melanoma (2019) (1)
- Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts) (2019) (1)
- Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases (2022) (1)
- Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021 (2022) (1)
- Representativeness of initial skin biopsies showing pure desmoplastic melanoma: implications for management. (2023) (1)
- Residual melanoma in wide local excision specimens after 'complete' excision of primary cutaneous in situ and invasive melanomas. (2021) (1)
- Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. (2022) (1)
- Lentigo maligna: defining margins and predictors of recurrence utilizing clinical, dermoscopic, confocal microscopy and histopathology features (2021) (1)
- Circulating tumor DNA (ctDNA) in patients (pts) with metastatic uveal melanoma (UM) treated with protein kinase C inhibitor (PKCi). (2020) (1)
- Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). (2022) (1)
- Obesity is associated with altered tumor metabolism in metastatic melanoma. (2022) (1)
- Cutaneous clear cell sarcoma with an epidermal component mimicking melanoma. (2021) (1)
- Abstract 3876: TRIM16 is a prognostic marker for patients with lymph node metastatic melanoma. (2013) (1)
- wild-type melanomas have a high mutation load correlating with histological and molecular signatures of UV damage (2013) (1)
- Correlation between pre-existing MEK1P124 mutations and clinical and in vitro response to BRAF inhibitors in metastatic melanoma. (2014) (1)
- Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome Project. (2017) (1)
- P01.15 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to interferon-gamma (IFN-gamma) signature – the DONIMI study (2020) (1)
- Cross-Platform Omics Prediction procedure: a game changer for implementing precision medicine in patients with stage-III melanoma (2020) (1)
- Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). (2022) (1)
- Abstract 3271: Different pathologic response rates between Australia and Europe in macroscopic stage III melanoma patients upon neoadjuvant ipilimumab plus nivolumab in the phase II OpACIN-neo trial (2020) (1)
- Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation (2022) (1)
- Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. (2022) (1)
- Tumor CD155 Drives Resistance to Immunotherapy by Downregulating the Activating Receptor CD226 in CD8 + T Cells (2019) (1)
- Abstract 1977: The protein phosphatase 2 subunit PR48 is a novel melanoma tumor suppressor gene. (2013) (1)
- Abstract 2968: Exome sequencing of desmoplastic melanoma reveals recurrent NFKBIE promoter mutations and diverse MAPK/PI3K pathway activating mutations (2015) (1)
- Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. (2021) (1)
- First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality (2015) (1)
- Abstract 2761: CODEX highly multiplex image mapping to CITEseq datasets reveal the spatial dynamics of the TME during the development of acquired resistant in immunotherapy treated melanoma (2021) (1)
- Reflectance confocal microscopy – a non‐invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma (2022) (1)
- Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021 (2022) (1)
- 23. Primary Melanoma of the Lung (2012) (1)
- Outcome in 846 cutaneous melanoma patients from a single center after negative sentinel node biopsy (2006) (1)
- Hypoxia controls the glycome signature and galectin-8 - ligand axis to promote pro-tumorigenic properties of metastatic melanoma. (2022) (1)
- Tumor-associated B-cells induce tumor heterogeneity and therapy resistance (2017) (1)
- Genetc and morphologic features for melanoma classification: implications for clinical trials (2010) (1)
- Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase II OpACIN-neo trial (2019) (1)
- ASO Visual Abstract: Evaluation of Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International Multicenter Study (2022) (1)
- 27. Pathological features of metastases from primary cutaneous desmoplastic melanoma (2011) (1)
- ASO Author Reflections: Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas (2018) (1)
- A case report of primary cutaneous ewing’s sarcoma / primitive neuroectodermal tumour (ES/PNET) (2011) (1)
- Diagnosing melanoma: the method matters (2019) (1)
- Sentinel lymph node biopsy remains the most accurate method of obtaining staging and prognostic information for patients with primary cutaneous melanomas (2018) (1)
- Dataset for the Reporting of Merkel Cell Carcinoma (2022) (1)
- Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1). (2019) (1)
- Magnetic resonance spectroscopy in the management of melanoma (2005) (1)
- Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only, compared to therapeutic lymph node dissection: First results of the PRADO trial. (2020) (1)
- Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy (2019) (1)
- Recent advances and important issues in melanoma pathology: an update for oncologists (2012) (1)
- Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis (2018) (1)
- Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma. (2019) (1)
- Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients (2017) (1)
- Hotspot KRAS mutations in brain metastases at the first metastatic recurrence of cutaneous melanoma (2020) (1)
- Multiple eruptive squamoproliferative lesions during anti‐PD1 immunotherapy for metastatic melanoma: Pathogenesis, immunohistochemical analysis and treatment (2022) (1)
- Circulating tumor DNA (ctDNA) using Guardant360 to predict response in BRAF V600 WT metastatic melanoma (MM) patients (pts) receiving immune checkpoint inhibitors (ICI). (2020) (1)
- Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. (2022) (1)
- 17 – Cutaneous Metastases (2010) (1)
- Melanomas in children and adolescents: Clinicopathologic features and survival outcomes. (2022) (1)
- Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (< 0.1 mm) Sentinel Lymph Node Metastases (2017) (1)
- Publication metrics: it really is all about the numbers. (2021) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Abstract 913: Defining melanoma patients unresponsive to single agent anti-PD-1 therapy but responsive to combination anti-PD-1 + anti-CTLA-4 therapy (2020) (1)
- Abstract 4718: Inositol polyphosphate 4-phosphatase II activates PI3K/SGK3 signaling to promote proliferation of human melanoma cells (2015) (1)
- Staging for Melanoma - Toward a New Paradigm? (2020) (1)
- History of Melanoma (2018) (1)
- The Importance of Population-Based Estimates of Melanocytic Pathology. (2018) (1)
- The critical role of tumour-resident cytotoxic T cells in human malignancies (2018) (0)
- Combined Melanocytic Nevi (2019) (0)
- Melanoma In-situ: A Patterns-of-care Study In New South Wales (nsw) (2008) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis (2019) (0)
- Review Genetic Alterations and Personalized Medicine in Melanoma (2014) (0)
- Response to Letter to the Editor: “Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes” (2020) (0)
- Long-term prospective assessment of quality of life and lymphedema after inguinal or inguinal and pelvic lymphadenectomy for recurrent melanoma in the groin (2016) (0)
- Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors (2021) (0)
- Abstract B8: Galectin-1 expressed in human melanoma is bound to cancer stem cells: A driver for metastatic progression and target for antimetastatic cancer therapy (2013) (0)
- Correction to: Histological regression in melanoma: impact on sentinel lymph node status and survival (2021) (0)
- 38. INTRALESIONAL MOLECULAR HETEROGENEITY IN A BRAF-MUTANT BRAF INHIBITOR RESISTANT MELANOMA: A CASE ILLUSTRATING THE CHALLENGES FOR PERSONALISED MEDICINE (2013) (0)
- Uncommon Variants of Melanoma and Collision Scenarios (2019) (0)
- 3 Tesla Magnetic Resonance (MR) Microimaging of Primary Cutaneous Melanoma (2006) (0)
- The utility of molecular testing in the recognition of undifferentiated metastatic melanoma (2022) (0)
- Abstract 81: The association between melanoma liver metastases (mets) and the systemic anti-tumor immune profile (2023) (0)
- Pathology (1943) (0)
- Breast Cancer and Melanoma Metastases in Regional Lymph Nodes Identified Using In Vivo Proton Magnetic Resonance Spectroscopy at 3 Tesla (2006) (0)
- The role of CD16+ NK cells and CD16+ CD56– cells in predicting response to anti-PD-1 therapy (2018) (0)
- Novel Immune Targets in Melanoma—Response (2019) (0)
- MCV status does not impact on histological and clinical characteristics of european and australian merkel cell carcinomas (2010) (0)
- Human Cancer Biology BRAF / NRAS Wild-Type Melanomas Have a High Mutation LoadCorrelatingwith Histologic andMolecular Signatures of UV Damage (2013) (0)
- Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy. (2017) (0)
- Erratum (2014) (0)
- Reply to I. Satzger et al (2011) (0)
- A LACK OF ACTIONABLE MUTATIONS IN PHYLLODES TUMOURS OF THE BREAST (2013) (0)
- Assessment of the prognostic role of regression in primary cutaneous melanoma (2020) (0)
- A subcutaneous nodule: another variant of a pseudotumour? (2009) (0)
- Deep Penetrating Nevi (2019) (0)
- The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro (2008) (0)
- SURGEON-LED BIOPSY WITH INTRAOPERATIVE FROZEN SECTION IS AN ACCURATE AND COST EFFECTIVE METHOD FOR INITIAL EVALUATION OF MUSCULOSKELETAL SARCOMAS. (2009) (0)
- Molecular Genomic Profiling of Melanocytic Nevi (2019) (0)
- A sheep in wolf's clothing: Agminated blue naevi masquerading as in-transit melanoma metastases. (2023) (0)
- Granuloma Annulare as a Paraneoplastic Rash in a Patient With Poem Syndrome (0)
- Melanocytic Nevi in Lymph Nodes (2019) (0)
- Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+ T cells (PD1tR) driven by tumour CD155 (2019) (0)
- Can histologic parameters of melanoma metastases in sentinel lymph nodes reliably select patients who can be safely spared completion lymph node dissection? (2010) (0)
- Correct identification of a sentinel node postselective lymphadenectomy using antimony levels. (2008) (0)
- EXPRESSION OF THE OLIGODENDROCYTE‐SPECIFIC ANTIGEN CNPase IN HUMAN GLIOMAS (2001) (0)
- 5. Endocrine mucin producing sweat gland carcinoma (2012) (0)
- Abstract 2369: Spatial organization of the tumour immune microenvironment (TIME) in primary and metastatic melanoma is associated with patient outcome (2023) (0)
- 074 Predicting recurrence in primary melanomas by T cell receptor immunosequencing (2018) (0)
- Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers (2022) (0)
- Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. (2022) (0)
- Letter to the Editor (2003) (0)
- Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis (2019) (0)
- Pathological re-classification of basal cell carcinomas from the ontrac skin cancer chemoprevention study and the new who skin blue book (2019) (0)
- SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling (2018) (0)
- 24. The prognostic value of mitotic rate in recurrent melanoma (2011) (0)
- Publisher Correction: Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence (2020) (0)
- 32. Primary synovial sarcoma of the mediastinum (2012) (0)
- OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8TH EDITION STAGE III MELANOMA PATIENTS (2019) (0)
- Abstract 2609: Hypoxia-mediated downregulation of GCNT2/I-antigen in metastatic melanoma accelerates disease progression and mortality (2021) (0)
- Abstract LB-121: Exploring the germ-line contribution to exceptional response to PD-1/PD-L1 inhibition in patients with metastatic non-small-cell lung cancer by whole genome sequencing (2018) (0)
- Lentigo maligna/lentigo maligna melanoma in young patients in Australian tertiary centres. (2023) (0)
- Epigenetic profiling for the molecular classification of metastatic brain tumors (2018) (0)
- Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now. (2023) (0)
- Abstract 2420: Skp2-mediated stabilization of MTH1 promotes survival of melanoma cells upon oxidative stress (2018) (0)
- Increased expression of proteins from the G1/S transition of the cell cycle are important in progression in mammary phyllodes tumours (2009) (0)
- The deacylase SIRT5 supports melanoma viability by regulating chromatin dynamics (2020) (0)
- GLI activated nested malignant epithelioid cell tumour (2020) (0)
- 23. Comparison of pathological features of multiple primary cutaneous melanomas (2011) (0)
- Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort. (2023) (0)
- Randomized Trial of Whole-Brain Radiation Therapy in Melanoma Brain Metastases: First Interim Analysis (2014) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- Skin cancer: non-melanoma (2016) (0)
- 35. Factors predictive of clinical outcomes in patients with thin cutaneous melanoma (2011) (0)
- Abstract A04: Analysis of molecular and immune features that correlate with serum lactate dehydrogenase (LDH) levels in patients (pts) with metastatic melanoma (2020) (0)
- Defining moments in medicine. Pathology. (2001) (0)
- Quantifying the additional prognostic value of sentinel lymph node status over established clinicopathologic primary tumor features for predicting survival outcomes in melanoma patients. (2020) (0)
- Distinct Immune Cell Popu lations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1 / Anti-CTLA-4 Combined Therapy Graphical (2019) (0)
- Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting (2022) (0)
- Abstract 5701: Predictive biomarker models of immunotherapy response in patients with metastatic melanoma: genomic, transcriptomic, and immune profiles from the Personalised Immunotherapy Program (PIP) (2023) (0)
- Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. (2023) (0)
- The effect of organ-specific tumor microenvironments on response patterns to immunotherapy (2022) (0)
- Genomic Landscape of Patient-matched Tumor and Circulating Cell-free DNA in Metastatic Melanoma (2019) (0)
- Issue Information ‐ TOC (2018) (0)
- (S029) Development of an Immune-Associated Molecular Signature Predicting Melanoma Survival (2017) (0)
- Wednesday 20 February 2008 (2007) (0)
- Corrigendum to "The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment" [Lung Cancer 165C (2022) 124-132]. (2022) (0)
- ASO Author Reflections: Surgical Resection May Improve the Outcome for Patients with Residual Metastatic Melanoma When Modern Systemic Therapies Have Not Achieved Complete Disease Control (2021) (0)
- Increased expression of Mcl-1 and Bcl-XL and decreased expression of Bcl-2 associated with melanoma progression and transcription factors (2006) (0)
- Melanoma management in 2007. -letter- (2007) (0)
- Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC) (2022) (0)
- Abstract LB-031: Deciphering distinct roles of RASA2 in melanomagenesis (2017) (0)
- 33. Snore (non-Sentinel Node Risk score): a system for accurately stratifying risk of non-sentinel node positivity in cutaneous melanoma patients with positive sentinel lymph nodes (2011) (0)
- Genomic alterations in metastatic basal cell carcinoma (2020) (0)
- Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation–positive melanoma with metastases to the brain (BRV116521). (2014) (0)
- Biomarkers of response and resistance to combined anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients utilising multiplex immunofluorescence (2018) (0)
- L1CAM and laminin vascular network: Association with the high-risk replacement histopathologic growth pattern in uveal melanoma liver metastases. (2022) (0)
- Plain Language Summary - Development and validation of risk calculators for people with "thin" melanomas on their skin to predict the likelihood that their cancer will return. (2023) (0)
- Cross-Platform Omics Prediction procedure: a statistical machine learning framework for wider implementation of precision medicine (2022) (0)
- DP02: AMBLor: an immunohistochemical prognostic biomarker to identify low‐risk nonulcerated cutaneous AJCC stage I/II melanomas (2022) (0)
- REDUCED EXPRESSION OF SOCS3 PREDICTS POOR OUTCOME IN EPITHELIAL OVARIAN CANCER (2004) (0)
- General practitioners’ involvement in diagnosing, treating and referring patients with suspected or confirmed primary cutaneous melanoma: a qualitative study (2019) (0)
- Abstract 2206: Proteome phenotype of stage III metastatic melanoma and response to MEK inhibition (2017) (0)
- Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. (2021) (0)
- IFNγ signaling sensitizes melanoma cells to BH3 Mimetics. (2023) (0)
- Test and Teach Number Ninety Four: Part 2 (1999) (0)
- The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma (2023) (0)
- Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas (2022) (0)
- ASO Visual Abstract: Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-transit Melanoma Metastases (2022) (0)
- 19. The many faces of colonic malakoplakia: A case series and review of the literature (2020) (0)
- Abstract 56: Receptor-Interacting protein kinase 1 functions as an oncogenic regulator in human melanoma (2015) (0)
- Case report of superficial acral fibromyxoma (2012) (0)
- Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy (2019) (0)
- 32. Sentinel lymph node biopsy in patients with thin melanoma (2011) (0)
- Melanoma guide for GPs (2012) (0)
- Loss of Noxa and Puma have inverse effects on melanomagenesis in a predisposed, genetically-defined mouse melanoma model (2013) (0)
- 42. Glycogen synthase kinase 3 is implicated in tumour progression in melanoma (2012) (0)
- Abstract 6747: Sites of metastases prior to systemic treatment influence progression patterns and survival in stage IV melanoma patients (2023) (0)
- 9. EGFR over expression, not amplification, is involved in the pathogenesis and progression of mammary phyllodes tumours (2010) (0)
- Letter to the Editor (2003) (0)
- Desmoplastic Melanoma (2019) (0)
- Abstract A024: Protein microarrays for the immunological profiling of melanoma (2016) (0)
- External Validation in an Australian Population of the EORTC-DeCOG Nomogram Predicting Recurrence, Distant Metastasis and Overall Mortality in Melanoma Patients with Positive Sentinel Lymph Nodes (2023) (0)
- In vivo reflectance confocal microscopy can detect the invasive component of lentigo maligna melanoma: prospective analysis and case- control study. (2023) (0)
- Comparison of Humans Versus Mobile Phone-Powered Artificial Intelligence for the Diagnosis and Management of Skin Cancer: A Multinational Prospective Diagnostic Clinical Trial (2022) (0)
- 31. Prognostic importance of the extent of ulceration of clinically localised cutaneous melanoma (2011) (0)
- A 14‐Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma (2018) (0)
- Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases. (2022) (0)
- 3304 Metabolic activity in metastatic melanoma after long-term treatment with anti-PD-1 antibodies (2015) (0)
- Test and teach. Diagnosis: Subcutaneous Rosai-Dorfman disease. (2002) (0)
- Expression of cancer-testis antigens in late stage melanoma is associated with high FoxP3 expression in tumour infiltrating lymphocytes in early stage disease (2010) (0)
- Causes, consequences and clinical significance of aneuploidy across melanoma subtypes (2022) (0)
- Pathology: the next chapter. (2021) (0)
- Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach (2023) (0)
- OP-JNCI200009 873..874 (2020) (0)
- Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue Nevi (2022) (0)
- Test and teach. Number ninety-four: Part 1. Churg-Strauss syndrome. (1999) (0)
- Acral and Subungual Melanoma (2019) (0)
- Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma (2022) (0)
- Abstract 2762: Spatial distribution and immune cell infiltration at different sites of melanoma metastases (mets) (2021) (0)
- Effect of Histopathological Explanations for Dermoscopic Criteria on Learning Curves in Skin Cancer Training: A Randomized Controlled Trial (2023) (0)
- PD-L1 expression and association with patient outcome in a large pediatric cohort (2016) (0)
- Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. (2019) (0)
- Abstract LB-146: T cell receptor immunosequencing improves prediction of melanoma recurrence (2018) (0)
- Micrometastatic Melanoma Cell Accumulation in Sentinel Lymph Nodes Containing Dendritic + Long-Term Protective Effect of Mature DC-LAMP (2007) (0)
- LNK suppresses interferon signaling in melanoma (2019) (0)
- IMMU-04. TEMPORAL AND SPATIAL MODULATION OF THE IMMUNE RESPONSE OF THE MURINE GL261 GLIOMA TUMOUR MICROENVIRONMENT (2019) (0)
- RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells (2018) (0)
- 6. Extraskeletal myxoid chondrosarcoma of the tongue: a case report (2012) (0)
- Temporal and spatial modulation of the immune response of the murine Gl261 glioma tumor microenvironment (2019) (0)
- Competing risks analysis with missing cause-of-failure—penalized likelihood estimation of cause-specific Cox models (2022) (0)
- The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence (2020) (0)
- 25. The prognostic importance of tumour-infiltrating lymphocyte grade in patients with primary cutaneous melanoma (2011) (0)
- The Prognostic Significance of Isolated HMB-45 or MelanA – Positive Cells in Melanoma Sentinel Lymph Node In Response : (2008) (0)
- Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic Targets. (2023) (0)
- 4. Well-differentiated liposarcoma with unusual vascular component (2012) (0)
- Clinical and histologic features of level 2 cutaneous malignant melanoma associated with metastasis (2002) (0)
- Primitive non-neural granular cell tumour of skin: report of a case (2014) (0)
- Abstract 2221: Molecular analysis finds excision margin width predictive of recurrence in acral melanoma (2022) (0)
- Translating Basic Cancer Discoveries to the Clinic. (2020) (0)
- bcGST - an interactive bias-correction method to identify over-represented gene-sets in boutique arrays (2017) (0)
- Abstract A154: Flow cytometric analysis of immune responses in the melanoma tissue biopsies before or during anti-PD1 immunotherapy (2019) (0)
- Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors. (2017) (0)
- The role of GRP78, p-ERK and Bcl-2 proteins in endoplasmic reticulum stress-induced apoptosis and anti-apoptosis in melanoma (2009) (0)
- Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma. (2022) (0)
- A light shines on melanoma metastagenesis (2014) (0)
- Mutational analysis of undifferentiated melanoma (2020) (0)
- 1. MUTATIONAL ANALYSIS OF BRM IN HUMAN SKIN CANCER (2013) (0)
- Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma (2023) (0)
- Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Long-term results from the NeoCombi trial. (2022) (0)
- Abstract 5528: The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene (2017) (0)
- BRAF Inhibitor Treatment BRAF-Mutant Melanoma Patients during Growth Factor Serum Levels in Dynamics of Chemokine , Cytokine , and (2014) (0)
- PD-L1 expression, immune cell correlates, and PD-1+ lymphocytes in sentinel lymph node positive melanoma patients: Implications for adjuvant PD-1 clinical trials. (2015) (0)
- Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework (2022) (0)
- 21. Recurrent hotspot SF3B1 mutations in mucosal melanoma: Frequency and impact on survival (2019) (0)
- Analysis of clinical and molecular profiles of patients with innate resistance to ANTI-PD-1 +/- ANTI-CTLA-4 immunotherapy in metastatic melanoma (2021) (0)
- Diagnostic Musculoskeletal Surgical Pathology: Clinicoradiologic and Cytologic Correlations (2005) (0)
- Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma (2023) (0)
- Junctional Nevus and Early Melanoma on Sun-Damaged Skin of the Head/Neck: a Clinico-Pathologic Challenge. (2023) (0)
- Data Descriptor : Brain metastasis DNA methylomes , a novel resource for the identi fi cation of biological and clinical features (2019) (0)
- Sentinel lymph node biopsy in pediatric and adolescent cutaneous melanoma (2009) (0)
- Fine needle aspiration biopsy of the pancreas (2000) (0)
- Re: NM patients and SN. (2007) (0)
- Approaches to classification and management of histologically ambiguous/ borderline / primary cutaneous melanocytic tumours (2011) (0)
- Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing (2017) (0)
- Abstract 3246: Dynamics of T-cell checkpoint receptor profiles during melanoma progression (2019) (0)
- 24. Analysis of indoleamine 2,3-dioxygenase expression in longitudinal primary, nodal and distant metastatic melanoma specimens (2019) (0)
- Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells (2019) (0)
- Abstract 2650: In depth immune profiling of the response of melanoma to MAPK inhibition (2016) (0)
- Effect of the SunSafe Student Ambassador Program on the attitudes, knowledge and behaviour of Australian high‐school students towards sun safety: a prospective study (2022) (0)
- Understanding the Tumour Immune Microenvironment (TIME) at different sites of MELANOMA Metastases (METS) (2020) (0)
- Erratum to: Clinicopathologic Features of Incident and Subsequent Tumors in Patients with Multiple Primary Cutaneous Melanomas (2012) (0)
- Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients (2014) (0)
- Trabectedin-induced treatment effects in myxoid liposarcoma refractory to previous chemotherapy (2012) (0)
- Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets (2019) (0)
- Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. (2020) (0)
- Evolving concepts in soft tissue pathology (2004) (0)
- 426 MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma (2020) (0)
- Case report of a challenging medium‐sized congenital melanocytic nevus (CMN): Highlighting a role for reflectance confocal microscopy (RCM) for evaluating changing CMN in children (2021) (0)
- P1.04-11 Exploring the Germ-Line Contribution to Exceptional Response to PD-1/PD-L1 Inhibition in Patients with NSCLC by Whole Genome Sequencing (2018) (0)
- Phosphatidylinositol 4,5-Bisphosphate 5-Phosphatase A regulates PI3K/Akt signaling in human melanoma cells (2011) (0)
- 23. Prevalence and expression profile of immune checkpoint receptors in untreated human melanoma (2019) (0)
- 34. Association of histological features of metastatic melanoma in sentinel lymph nodes with lymph node recurrence, distant metastasis and survival (2011) (0)
- 26. Lymphoma arising in patients with cutaneous melanoma (2011) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- 17. Peritoneal epithelioid mesothelioma in a patient with metastatic melanoma - an association seen in BAP1 mutations (2014) (0)
- 1029 High throughput TCR sequencing greatly improves prediction of recurrence in primary melanomas (2019) (0)
- Whole exome paraffin sequencing (WEPS) of same-patient (pt) primary, extracranial, and melanoma brain metastases (PEB) to identify new driver and clonal evolution genetic events. (2015) (0)
- Characterizing the Clinical Implications of Histologic Regression in Melanoma Requires Clear Diagnostic Criteria That Are Consistently Applied-Reply. (2021) (0)
- Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy. (2023) (0)
- Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomes (2022) (0)
- Successful Manufacturing of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy from Cryopreserved Melanoma Tumors Shipped from Australia (2022) (0)
- Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes (2022) (0)
- DP01: Getting the whole picture on melanoma diagnosis: investigating the effects of clinical images and dermoscopy report on the histopathology diagnosis of melanocytic skin lesions (2022) (0)
- Melanoma Prognosis and Staging (2019) (0)
- REPLY to MS#JAAD-D-23-00002R1. (2023) (0)
- Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance. (2018) (0)
- Author Correction: Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin (2019) (0)
- Medical > In Vivo > Inflammatory Disease Research 28 (2018) (0)
- Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours (2020) (0)
- Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas (2021) (0)
- Benign blue naevi involving lymph nodes: A case series with accompanying molecular data and long term follow-up confirms clinical behaviour (2020) (0)
- Atlas of Genetics and Cytogenetics in Oncology and Haematology Skin : Spitz tumors (2013) (0)
- Preclinical Development A High-Throughput Panel for Identifying Clinically Relevant Mutation Pro fi les in Melanoma (2012) (0)
- Abstract 5025: Immune expression profiling of MAPK inhibitor resistant tumors based upon mechanisms of resistance (2015) (0)
- ASO Visual Abstract: Survival Outcomes of Salvage Metastasectomy after Failure of Modern-Era Systemic Therapy for Melanoma (2021) (0)
- 37. ANGIOTROPISM IS AN INDEPENDENT PREDICTOR OF MICROSCOPIC SATELLITES IN PRIMARY CUTANEOUS MELANOMA (2013) (0)
- Assessment of a New Predictive Score for Non-sentinel Node Positivity in Melanoma Patients (2012) (0)
- Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread (2022) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- Isolated limb infusion for the treatment of advanced extremity soft tissue sarcomas (2001) (0)
- Neurocognitive outcomes in a phase-3 randomised trial comparing adjuvant whole brain radiotherapy with observation after local treatment of brain metastases in patients with melanoma (2019) (0)
- Re: Reply to letter to the editor re: ‘practical guide on the use of imiquimod cream to treat lentigo maligna’ (2022) (0)
- Mucosal Melanoma: A Review Emphasizing the Molecular Landscape and Implications for Diagnosis and Management. (2021) (0)
- Combination of avelumabwith peptide receptor radionuclide therapy (PRRT) or conventional fractionated radiotherapy (RT) in metastatic merkel cell carcinoma (mMCC) [GoTHAM study] (2019) (0)
This paper list is powered by the following services:
Other Resources About Richard Scolyer
What Schools Are Affiliated With Richard Scolyer?
Richard Scolyer is affiliated with the following schools:
